On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
For Peptide, Antibody, Hormone, And Protein Detection
Enzyme-linked immunosorbent assays (ELISA) are the most common method for ligand binding assays, and are a core competency for the BioAgilytix team. We use ELISA in both its original and automation-powered forms as a fast, reliable, and cost-effective platform for analyte quantification of specific assays used for testing of biologics as well as cell and gene therapies.
What are your specific assay needs? Let’s schedule a conversation to review your questions and requirements
with one of our scientists.
The ELISA method is designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones, and is typically performed on a 96-well plate. Using ELISA, detection is completed by assessing the conjugated enzyme activity via incubation with a substrate to produce a measurable signal.
The binding and immobilization of reagents done through ELISA makes it easy to separate bound from non-bound material during the assay, and wash away non-specifically bound materials to measure specific analytes.
The ELISA technique was originally developed in the 1970s, when it was created as a replacement for traditional radioimmunoassay methods. More recently however, the ELISA method has been paired with laboratory automation techniques to dramatically improve throughput and sensitivity. Such advancements include automated plate washing and automated readouts.
Learn why ELISA is still the most used immunoassay platform for supporting large molecule bioanalysis in this featured blog from a platform expert.
The ELISA method is one of the most diverse available, with applications throughout health care and large molecule laboratory science. The platform comes in a variety of mechanisms, including direct, indirect, sandwich, competitive and ELISpot, each with its own optimal applications.
As a bioanalytical laboratory that harnesses a variety of platforms, BioAgilytix most frequently leverages ELISA in our work with biomarkers, immunogenicity, pharmacokinetics (PK), and cell-based assays. ELISA can be leveraged in a multitude of research areas, including oncology, cardiovascular, neuroscience, and gene and cell therapies. Specifically, ELISA can be used to evaluate antibodies to specific HLA haplotype expressed by allogenous cell therapy, and supports assessment of immunogenicity, both humoral and cellular response, to the transgene, vector, and lipid nanoparticle used in cell and gene therapies.
Even after more than 40 years of widespread use, the ELISA method is still widely regarded for its many advantages. Aside from its original benefit of not requiring radioisotopes or radiation-measurement equipment and its use of fluorescence, ELISAs offer high sensitivity, specificity, adaptability and reliability when compared to other techniques.
The ELISA plate will passively bind antibodies and proteins, and is then developed by adding an enzymatic substrate to produce a visible signal that indicates the quantity of antigen is captured on a plate and followed by incubation with the detection antibody.
This binding and immobilization of reagents makes it easy to separate bound from nonbound material during the assay, and wash away nonspecifically bound materials to measure specific analytes.
Platform In Action
Learn how automation is helping analysts address growing pressures to increase efficiency and output with limited resources.
BioAgilytix offers ELISA services as a central competency, and has extensive experience developing, optimizing, and validating ELISA tests. Our team is proficient in single analyte and multiplexed analyses, with traditional colorimetric readouts as well as electrochemoluminescence readouts with MSD technology. We run bioanalytical ELISA assays across the range of biological matrices — from serum and plasma to urine and cell and tissue lysate. In fact, we have developed ELISA assays for:
Our equipment includes Biotek Synergy 2 plate reader instruments, Grifols Triturus automated platform (x2) and Molecular Devices SpectraMax 380 and m5e plate readers, as well as MSD QuickPlex SQ120.
Our scientific team brings extensive, proven experience working with this popular platform to deliver high precision, high throughput assays to support testing of biologics, cell therapies, and gene therapies, and most often leverage ELISA to meet our clients’ most demanding ligand-binding assay challenges.
Learn how we can support your unique assay requirements with the ELISA method today.